#ASCO14 - Poster: Predicting response to abiraterone acetate: mRNA biomarker analysis of study COU-AA-302

CHICAGO, IL USA (UroToday.com) - Presented by Deborah Ricci,1 Weimin Li,2 Thomas W. Griffin,3 Michael Gormley,2 Erin Henitz,1 Charles J. Ryan,4 Johann S. de Bono,5 Gerhardt Attard,5 Alfons J.M. van den Eertwegh,6 Dirk Schrijvers,7 John Gullo,8 Henrik Suttmann,9 Joan Carles,10 Jose M. Piulats Rodriguez,11 Robert J. Jones,12 Christopher J. Logothetis,13 Dana E. Rathkopf,14 Howard I. Scher,14 and Eleni Efstathiou13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 abiraterone Ricci thumb

1Janssen Research & Development, Raritan, NJ USA
2Janssen Research & Development, Spring House, PA USA
3Janssen Research & Development, Los Angeles, CA USA
4University of California San Francisco, San Francisco, CA USA
5The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK
6VU University Medical Center, Amsterdam, The Netherlands
7ZNA Middelheim Oncology Clinic, Antwerp, Belgium
8Hematology Oncology Associates of CNY, East Syracuse, NY USA
9Urologikum Hamburg, Hamburg, Germany
10Hospital Universitari Vall d´Hebron (Vall d’Hebron University Hospital), Barcelona, Spain
11Institut Català d’Oncologia L’Hospitalet, Barcelona, Spain
12The Beatson West of Scotland Cancer Centre, Glasgow, UK
13The University of Texas MD Anderson Cancer Center; Houston, TX USA
14Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY USA